Icon

Zonisade - (100 mg/5 mL ; Oral Suspension)

Zonisamide Azurity (Arbor)
100 mg/5 mL ; Oral Suspension
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
None
None None
ZONISADE is indicated as adjunctive therapy for the treatment of partial-onset seizures in adults and pediatric patients 16 years of age and older
Yes
Zonisade Patent 1 Patent 2
***** **** ** *** **, **** **** ** *** **, ****
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** *** \ ********* **** **, **** ******* ******** *** ****** **** ****
  1. *** *, **** : * **** ** ** ***** *** ***** ** *** ***.
  2. *** **, **** : ***** ******** ******* ***** *** **** ** ******.
  3. *** *, **** : ******* **** ***** **** ************ ** ****** **. '*** *** '***.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.